Target intelligence / Profile preview

Epidermal growth factor receptor exon 19 deletion mutation (EGFR exon 19 deletion)

Target
EGFR exon 19 deletion
Molecular classification
Receptor tyrosine kinase, Enzyme, Receptor
01

Overview

The epidermal growth factor receptor exon 19 deletion mutation refers to a group of in-frame deletions within the region encoded by exon 19 of the EGFR gene. These deletions most commonly remove amino acids from positions E746 to A750 (notably ΔE746_A750), but many subtypes exist with varying start and end points and sometimes insertions or substitutions[1][2][4][7]. The mutations occur within the kinase domain's β3–αC loop—a critical region for enzymatic activity—resulting in increased autophosphorylation and constitutive activation of downstream signaling pathways such as AKT and STAT. This leads to enhanced cell survival and proliferation. These mutations are among the most frequent activating alterations found in non-small cell lung cancer (NSCLC), accounting for about half of all EGFR mutations detected clinically[2][4]. Tumors harboring these deletions are highly sensitive to several generations of EGFR tyrosine kinase inhibitors (TKIs) including erlotinib, gefitinib, afatinib, osimertinib, and lapatinib. The presence of an EGFR exon 19 deletion is a well-established predictive biomarker for response to these targeted therapies. There is significant heterogeneity among different subtypes regarding their clinical behavior and sensitivity to various TKIs; however, all confer increased sensitivity compared with wild-type EGFR[5][7]. Resistance can develop over time due to secondary mutations or alternative pathway activation. In summary: EGFR exon 19 deletions define a class-defining oncogenic driver alteration that is both diagnostically actionable as a biomarker and therapeutically targetable with multiple approved drugs in NSCLC patients[1][2][3][4].

Other names
EGFR 19delEGFR ΔE746_A750EGFR delE746_A750Epidermal growth factor receptor exon 19delErbB1 exon 19 deletion
02

Mechanism of action

Inhibition of mutant EGFR tyrosine kinase activity by competitive binding to the ATP-binding site, blocking downstream signaling pathways that drive cell proliferation and survival[1][3][4].

03

Biological functions

Signal transductionCell proliferationCell survivalApoptosis regulation
04

Disease associations

Cancer (especially non-small cell lung cancer)Other (rarely in other tumor types)
05

Safety considerations

Development of resistance mutations (e.g., T790M)Off-target effects leading to rash, diarrhea, interstitial lung disease with TKIs
06

Interacting drugs

Erlotinib

4 more in the full profile.

07

Biomarkers

Presence of EGFR exon 19 deletion mutation for patient selection in NSCLC therapy[4][6].

Beyond the preview

Go deeper on Epidermal growth factor receptor exon 19 deletion mutation (EGFR exon 19 deletion).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epidermal growth factor receptor exon 19 deletion mutation (EGFR exon 19 deletion).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call